Serum EphA2 as a Promising Biomarker for Early Detection of Colorectal Cancer
Author Information
Author(s): Sakuraba Shunsuke, Koizumi Akihiro, Iwasawa Takumi, Ito Tomoaki, Kato Kazunori, Scicchitano Pietro
Primary Institution: Juntendo University Medical School
Hypothesis
This study aimed to investigate the relationship between soluble EphA2 and colorectal cancer (CRC).
Conclusion
Serum EphA2 could serve as a valuable biomarker for the early detection of CRC.
Supporting Evidence
- Soluble EphA2 levels were significantly higher in patients than in healthy individuals.
- Even in early-stage cancer, there was a notable difference between healthy individuals and patients with Stage I CRC.
- Correlations were observed with tumor size, depth of invasion, and lymphatic invasion.
Takeaway
Doctors found that a substance called EphA2 in the blood can help spot colorectal cancer early, which is really important for treatment.
Methodology
Serum samples were collected from 65 patients with CRC and 19 healthy individuals, and soluble EphA2 levels were measured.
Limitations
The study was conducted in a single center with a relatively small sample size.
Participant Demographics
65 patients with CRC (42 males, 23 females) and 19 healthy individuals (10 males, 9 females) aged 30-50.
Statistical Information
P-Value
p = 0.00298
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website